Cognito Unveils New Brand to Reflect Enhanced Capabilities and Changing Markets
18.11.2022 15:28:00 EET | Business Wire | Press release
Cognito, the independent global communications agency, has today announced the launch of its new brand identity. Five years on from the last refresh, the new look and positioning reflects the agency’s growth and expansion across service lines, sectors and geographies to meet the needs of its global client roster. The agency’s client base comprises over 100 firms in finance, technology and professional services from the largest and best-known brands in the industry to dynamic start and scale ups.
The new brand design reflects the agency’s unique approach to solving business challenges, commitment to innovation and bringing new thinking and ideas to clients and the industry. It’s also an expression of the different perspectives and experiences Cognito holds across its global team; speaking over 20 languages, from over 15 countries from offices in the US, EMEA, and APAC.
Cognito has launched a dedicated Sustainability Practice to help clients with the Climate Transition. Earlier this year, Cognito also opened an office in Sydney to boost its reach across APAC alongside its core regional hubs in Hong Kong and Singapore.
Tom Coombes, Cognito’s Founder and CEO, comments: “The new Cognito brand reflects where we are as an agency, the services we offer, the geographies we work in and the strength of expertise we have. We know clients are facing increasingly complicated challenges. We believe that we can now offer unparalleled services across the communication and marketing mix. All our services and advice are designed for clients who work in complex and competitive markets. The new brand is a reflection of our appetite to help our clients thrive in these dynamic sectors and our ambition to be the agency of choice globally.”
Ends
About Cognito
Cognito is an independent global communications agency driving the conversations that matter for our clients in financial markets, technology and the climate transition. We champion them as they lead the way to sustainable development and a more connected world.
We advise organizations, from established leaders to startup challengers, on how to manage reputation, handle threats, and build value in complex and competitive markets. With creative content and an understanding of channel complexity, we protect and grow our clients’ businesses through purpose-driven communications and stakeholder engagement.
Our team of consultants around the world bring together 20 languages from 15 countries, with big agency and in-house expertise working across corporate communications, PR, digital marketing and social. You can find us on the ground in key financial markets - London, Amsterdam, New York, Los Angeles, Singapore, Hong Kong and Sydney - infusing local knowledge and culture in our 7 offices with multi- national resources, the same standards of excellence and a truly global perspective.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005219/en/
Contact information
Hannah Polson
Hannah.polson@cognitomedia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom